SEC Form 4 · accession 0001123292-16-002600
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Suzanne M. Hanlon
Officer — Sec, General Counsel & VP HR
Period of report
Aug 5, 2015
Accepted (ET)
Aug 17, 2016 · 2:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 5, 2015 | P | 3,000 | $17.92 | A | 3,000 | I | By spouse |
| Common StockF2 | Aug 16, 2016 | S | 3,000 | $10.53 | D | 0 | I | By spouse |
| Common Stock | holding | — | — | — | 39,893 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.47 to $10.70, inclusive. The reporting person undertakes to provide Zynerba Pharmaceuticals, Inc., any security holder of Zynerba Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.